Evidence map›Paper›PMID 31315986›Full record

ArticleJournal of virology2019

An Interaction with PARP-1 and Inhibition of Parylation Contribute to Attenuation of DNA Damage Signaling by the Adenovirus E4orf4 Protein.

Keren Nebenzahl-Sharon, Rakefet Sharf, Jana Amer, Hassan Shalata, Hanan Khoury-Haddad, Sook-Young Sohn, Nabieh Ayoub, Patrick Hearing, Tamar Kleinberger

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Identification of porcine PARP11 as a restricted factor for pseudorabies virus.Frontiers in cellular and infection microbiology · 2024
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. NADFrontiers in molecular biosciences · 2021
    Review
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Keren Nebenzahl-SharonDepartment of Molecular Microbiology, the Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel.
Rakefet SharfDepartment of Molecular Microbiology, the Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel.
Jana AmerDepartment of Molecular Microbiology, the Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel.
Hassan ShalataDepartment of Molecular Microbiology, the Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel.
Hanan Khoury-HaddadFaculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel.
Sook-Young SohnDepartment of Molecular Genetics and Microbiology, School of Medicine, Stony Brook University, Stony Brook, New York, USA.
Nabieh AyoubFaculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel.
Patrick HearingDepartment of Molecular Genetics and Microbiology, School of Medicine, Stony Brook University, Stony Brook, New York, USA.
Tamar KleinbergerDepartment of Molecular Microbiology, the Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel tamark@technion.ac.il.ORCID 0000-0002-0300-8679
Technion – Israel Institute of Technology · ILStony Brook University · US

Funding

Regulation of Nuclear Signaling Pathways by the Adenovirus E4-ORF3 ProteinR01CA122677 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI HEARING, PATRICK · 2007 to 2022
$5.2M
NCI NIH HHS R01 CA122677
6 · The paper itself

Abstract

The adenovirus (Ad) E4orf4 protein was reported to contribute to inhibition of ATM- and ATR-regulated DNA damage signaling during Ad infection and following treatment with DNA-damaging drugs. Inhibition of these pathways improved Ad replication, and when expressed alone, E4orf4 sensitized transformed cells to drug-induced toxicity. However, the mechanisms utilized were not identified. Here, we show that E4orf4 associates with the DNA damage sensor poly(ADP-ribose) polymerase 1 (PARP-1) and that the association requires PARP activity. During Ad infection, PARP is activated, but its activity is not required for recruitment of either E4orf4 or PARP-1 to virus replication centers, suggesting that their association occurs following recruitment. Inhibition of PARP-1 assists E4orf4 in reducing DNA damage signaling during infection, and E4orf4 attenuates virus- and DNA damage-induced parylation. Furthermore, E4orf4 reduces PARP-1 phosphorylation on serine residues, which likely contributes to PARP-1 inhibition as phosphorylation of this enzyme was reported to enhance its activity. PARP-1 inhibition is important to Ad infection since treatment with a PARP inhibitor enhances replication efficiency. When E4orf4 is expressed alone, it associates with poly(ADP-ribose) (PAR) chains and is recruited to DNA damage sites in a PARP-1-dependent manner. This recruitment is required for inhibition of drug-induced ATR signaling by E4orf4 and for E4orf4-induced cancer cell death. Thus, the results presented here demonstrate a novel mechanism by which E4orf4 targets and inhibits DNA damage signaling through an association with PARP-1 for the benefit of the virus and impacting E4orf4-induced cancer cell death.

Indexed as

DNA DamageHost-Pathogen InteractionsPoly ADP RibosylationSignal TransductionAdenoviridaeCell LineHumansPoly (ADP-Ribose) Polymerase-1Viral ProteinsVirus ReplicationE4orf4 protein, adenovirusPoly (ADP-Ribose) Polymerase-1Viral Proteinsadenovirusescancer cell deathDNA damage responseE4orf4 proteinPARP-1poly(ADP-ribose) polymerase 1PP2A

Identifiers

PMID31315986
PMCPMC6744226
OpenAlexW2956965289

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.